TELA Bio Inc (NAS:TELA)

Q1 2025 TELA Bio Inc Earnings Call Transcript

May 8, 2025 / 08:30 PM GMT

Release Date Price: $0.9905 (+4.26%)

Transcript 10-Q8-K

Key Points

Positve

TELA Bio Inc (TELA) reported a 12% year-over-year revenue growth in Q1 2025, reaching $18.5 million.
The company saw strong demand for its OviTex and OTex PRS products, with revenue growth of 15% and 2% respectively.
European business showed significant strength with a 17% growth over the first quarter of 2024.
TELA Bio Inc (TELA) reaffirmed its 2025 revenue expectation of $85 to $88 million, representing a growth of 23% to 27% over the full year 2024.
The company has successfully trained 25 new sales team members, enhancing its commercial organization and sales capabilities.

Negative

Gross margin decreased to 67.6% from 68.3% in the prior year period, primarily due to excess and obsolete inventory adjustments.
The company reported a net loss of $11.3 million in Q1 2025, compared to a $5.7 million loss in the prior year period.
There is a 10% tariff on products shipped from New Zealand, which is expected to negatively affect gross margin by 50 to 100 basis points.
PRS unit sales declined by 3% for the quarter after an unusually strong first quarter in 2024.
The company faces challenges with GPO bundling situations, being capped at 20% of volume share at certain hospitals.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

TELA.OQ - TELA Bio Inc
Q1 2025 TELA Bio Inc Earnings Call
May 08, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon ladies and gentlemen, and welcome to the Telebio first quarter 2025 earnings conference call. At this time, all participants are in listen-only mode. Following the prepared remarks, there will be a question and answer session. Please be advised that today's conference is being recorded. I would now like to turn the conference over to Louisa Smith from Gil Martin Group.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, Gerald, and good afternoon everyone. Earlier today, Telebio released financial results for the first quarter 2025. A copy of the press release is available on

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.